Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBA Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows. Read more.
Sharing some updates as I complete another trip around the sun
WEB5 hours ago · At the end of this week, I will complete another trip around the sun. This seemed like an appropriate time to provide you with updates on several columns I have shared in the past year. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, the future was uncertain. Despite my positive attitude, I …
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Primary goal met for IPF in Phase 3 clinical trial of nerandomilast
WEB4 days ago · A Phase 3 clinical trial testing Boehringer Ingelheim ’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the therapy outperformed a placebo at improving lung function or preventing its decline after a year, recently announced top-line data shows.
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. $15K award goes to researcher for work into IPF disease risk factors September 20, 2024; Learning to live with both sleep apnea and pulmonary fibrosis September 17, 2024; Navigating emotional ups and downs on my IPF journey September 17, 2024; Phase 2b trial tests AP01, inhaled pirfenidone, in progressive PF September 13, 2024; A new twist in my journey: Familial idiopathic ...
Top 10 Pulmonary Fibrosis Stories of 2021
WEBJan 3, 2022 · breathing exercises, Collagen turnover, esopremazole, MDM4, N115, pterostilbene, renin-angiotensin system, Salvianolic acid B, Top 10, TXR-1002, TXR-1007, Tyvaso, vitamin D. Pulmonary Fibrosis News counts down its top 10 most-read stories of 2021, noting what made each relevant for the PF community.
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
WEBSep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung function decline decreased by 62% with treatment at that dose.. Study results support moving BMS-986278 into global Phase 3 testing in a trial program being called ALOFT, according to the therapy’s developer, Bristol ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
WEBAug 16, 2019 · The average life expectancy of patients with pulmonary fibrosis is three to five years after diagnosis. However, early detection of the disease is key to slowing progression, and conditions such as chronic obstructive pulmonary disease (COPD) or pulmonary arterial hypertension (PAH) can impact disease prognosis.